AHB(SH:688639)2026-02-27 08:10Financial Performance - In 2025, the company achieved total operating revenue of RMB 288,579.86 million, a year-on-year increase of 32.50%[4] - The net profit attributable to the parent company was RMB 13,081.59 million, a decrease of 30.97% compared to the previous year[4] - Basic earnings per share fell to RMB 0.52, a decline of 36.59% year-on-year[4] - The company’s weighted average return on equity decreased to 5.02%, down 4.65 percentage points from the previous year[4] Assets and Equity - The total assets at the end of 2025 were RMB 577,861.68 million, reflecting a year-on-year growth of 15.82%[6] - The net assets attributable to the parent company increased to RMB 264,507.68 million, up 3.14% from the previous year[6] Product Pricing and Profitability - The average price of key products, valine and myo-inositol, decreased compared to the previous year, impacting overall profitability[7] - The increase in operating expenses due to the expansion of business scale contributed to the decline in profits[8] Strategic Focus and Risks - The company continues to focus on the biotechnology sector, aiming to enhance product sales and expand market presence despite external challenges[7] - The financial data presented is preliminary and subject to final audit, highlighting the need for investors to be aware of investment risks[9]